MedPath

A confirmatory trial of KIB-PIA in healthy volunteers.

Phase 2
Conditions
Japanese healthy volunteers
Registration Number
JPRN-UMIN000000472
Lead Sponsor
ational Hospital Organization Mie National Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

1. Defined history of H5N1 avian flu ( gived subjects ) 2. Previously H5 avian flu vaccinated ( gived subjects ) 3. Subjects who has induced anaphylaxis by substance of foods and drugs. 4. Any cllinically significant history of heart, vasculature, blood systems, respiratory, liver, kidney, digestive, neuropsychiatric disorder. 5. History of Guillain- Barre Syndrome and Acute-disseminated-encephalomyelitis. 6. Participation in any clinical trial within 4months. 7. Previous treatment for livevaccine within 27days, or inactivated vaccine( without influenza vaccine HA vaccine)/toxoid within 6days. 8. Previously influenza vaccine HA vaccine within 4months. 9. History of blood transfusion or gamma-globulin preparations within 3months, or massive dose therapy of gamma-globulin preparations (greater or equal 200 mg/kg ) within 6months. 10. Pregnant and probably pregnant subjects. 11. Others judged as being inappropriate for the subjects of the study by investigators.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Levels of HI antibody titer to H5 antigen 2. Levels of neutralization antibody titer to H5N1Influenza Virus 3. To assess AE/ADR ,and type/frequency/duration of side reaction by from after Day 0 to post examination day
Secondary Outcome Measures
NameTimeMethod
Evaluation of antibody reactivity of 5microgram and 15microgram
© Copyright 2025. All Rights Reserved by MedPath